3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-positive Breast Cancer
1
HER2-positive Advanced Gastric Cancer
1
HER2 Overexpression
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Surveys and Questionnaires
9
Cystectomy
6
Blood Specimen Collection
5
Neoadjuvant Therapy
4
Cystoscopy
4
Drug Therapy
3
avelumab
2
Urination
2
Urinary Diversion
2
Surgical Procedures, Operative
2
Radiotherapy
2
Pioglitazone
2
Microarray Analysis
2
Methods
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Immunohistochemistry
2
Defecation
2
Biopsy
2
5-aminolevulinic acid hexyl ester
2
trastuzumab deruxtecan
1
sargramostim
1
pembrolizumab
1
erdafitinib
1
enfortumab vedotin
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Watchful Waiting
1
Urinary Sediment Analysis
1
Therapeutics
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Urinary Bladder Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-05-01
DP-04
AstraZeneca
Recruiting
100 enrolled